CRS-2 patients displayed increased levels of proinflammatory intermediate CD14++CD16+ monocytes [41 (IQR, 24–78)/μL] compared to their CKD counterparts [35 (IQR, 18–43)/μL] (p = 0.04). This evidence concerns the gene CD14 and chronic kidney disease.